There are currently 140 clinical trials in Akron, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Hospital Medical Center of Akron, Akron Children's Hospital, Cleveland Clinic Akron General and Akron General Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )
NCT05568888
Recruiting
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, large simple trial to investigate the efficacy and safety of a single intravenous (IV) infusion of BE1116 in subjects who have traumatic injury, with confirmed or suspected acute major bleeding and / or predicted to receive a large volume blood product transfusion.
Gender:
All
Ages:
15 years and above
Trial Updated:
03/04/2024
Locations: Summa Health System - Akron Campus, Akron, Ohio
Conditions: Traumatic Injury
Register for Updates
Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction
NCT00673842
Recruiting
This study will assess whether an implantable defibrillator will increase the likelihood of survival in patients who have had a heart attack, have abnormal test results from a 24 hour heart monitor, and who have low normal heart function.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/01/2024
Locations: Northeast Ohio Cardiovascular Specialists, Akron, Ohio
Conditions: Myocardial Infarction, Sudden Death
Register for Updates
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary Central Nervous System Tumors
NCT04939597
Recruiting
This phase III trial compares memantine to usual treatment in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.
Gender:
All
Ages:
Between 4 years and 17 years
Trial Updated:
02/27/2024
Locations: Children's Hospital Medical Center of Akron, Akron, Ohio
Conditions: Central Nervous System Carcinoma
Register for Updates
Project: Every Child for Younger Patients With Cancer
NCT02402244
Recruiting
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Gender:
All
Ages:
25 years and below
Trial Updated:
02/27/2024
Locations: Children's Hospital Medical Center of Akron, Akron, Ohio
Conditions: Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Lymphoproliferative Disorder, Myeloproliferative Neoplasm, Stromal Neoplasm, Carcinoma In Situ, Malignant Solid Neoplasm, Desmoid Fibromatosis, Ganglioneuroma, Melanocytic Neoplasm, Neuroendocrine Neoplasm
Register for Updates
Exactech Shoulder Post Market Clinical Follow-up Study
NCT05603728
Recruiting
The objective of this study is to collect and evaluate long-term clinical and radiographic outcomes data in order to better understand the safety and performance of the shoulder arthroplasty over time. This study will follow subjects long-term for a minimum of 10-years, without an early-term restriction on the amount of time they will be followed.
Gender:
All
Ages:
21 years and above
Trial Updated:
02/23/2024
Locations: Crystal Clinic Orthopaedic, Akron, Ohio
Conditions: Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy, Ankylosing Spondylitis, Post-traumatic Osteoarthritis, Rheumatoid Arthritis, Fracture, Infections
Register for Updates
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
NCT04706013
Recruiting
The proposed clinical study is intended to evaluate oral P5P for the treatment of patients confirmed to have Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency via genetic analysis. There is an unmet clinical need for pharmaceutical grade P5P, as to date none has been made commercially available. Patients will receive pharmaceutical grade P5P according to their normal oral P5P dosing regimen, as previously established by their physicians.
Gender:
All
Ages:
All
Trial Updated:
02/22/2024
Locations: Akron's Children's Hospital, Akron, Ohio
Conditions: Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Register for Updates
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
NCT04831580
Recruiting
This is a randomized controlled trial to compare survival for patients who undergi robotic assisted laparoscopy versus open radical hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: Summa Health Jean and Milton Copper Pavilion, Akron, Ohio +1 locations
Conditions: Cervical Cancer
Register for Updates
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200
Recruiting
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/18/2024
Locations: GSK Investigational Site, Akron, Ohio
Conditions: Colonic Neoplasms, Neoplasms, Colon
Register for Updates
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
NCT04557735
Recruiting
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.
Gender:
All
Ages:
Between 1 month and 17 years
Trial Updated:
02/16/2024
Locations: Clinical Trial Site, Akron, Ohio
Conditions: Thrombotic Microangiopathy
Register for Updates
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
NCT02418442
Recruiting
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
Gender:
All
Ages:
21 years and below
Trial Updated:
02/13/2024
Locations: Akron Children's Hospital, Akron, Ohio
Conditions: Rheumatic Joint Disease
Register for Updates
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
All
Ages:
All
Trial Updated:
02/12/2024
Locations: Not set, Akron, Ohio
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Register for Updates
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
NCT05309668
Recruiting
This study is designed to define a dosing regimen and assess the pharmacokinetics(PK) and safety of the granule formulation; the study will also include descriptive analyses of exploratory efficacy endpoints. The study will inform the benefit risk profile of the granule formulation in children aged ≥ 1 to < 7 years with NF1 related symptomatic, inoperable PN.
Gender:
All
Ages:
Between 1 year and 6 years
Trial Updated:
02/07/2024
Locations: Childrens Hospital Medical Center - Akron, Akron, Ohio
Conditions: Neurofibromatosis Type 1
Register for Updates